Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection. The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators)
Timeframe: From date of vaccination and up to 3 years
Recovery of cardiac function in patients with previously documented abnormal cardiac function
Timeframe: Through study completion, an average of 3 years
Quality of life using validated instruments at baseline, 3 months, 12 months, and annually
Timeframe: Through study completion, an average of 3 years
Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually
Timeframe: Through study completion, an average of 3 years
Physical activity using validated instruments at baseline, 3 months, 12 months, and annually
Timeframe: Through study completion, an average of 3 years